Calcineurin inhibitors and NFAT-regulated gene expression

Calcineurin inhibitors (CNIs) have a narrow therapeutic window; therefore, regular monitoring of the drug is necessary to balance sufficient efficacy with minimal toxicity. Until now, monitoring of immunosuppressive drugs is performed by pharmacokinetic assessments, mainly by trough concentrations (...

Full description

Saved in:
Bibliographic Details
Main Authors: Sommerer, Claudia (Author) , Meuer, Stefan (Author) , Zeier, Martin (Author) , Giese, Thomas (Author)
Format: Article (Journal)
Language:English
Published: 2012
In: Clinica chimica acta
Year: 2011, Volume: 413, Issue: 17-18, Pages: 1379-1386
ISSN:1873-3492
DOI:10.1016/j.cca.2011.09.041
Online Access:Verlag, Volltext: http://dx.doi.org/10.1016/j.cca.2011.09.041
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0009898111005493
Get full text
Author Notes:Claudia Sommerer, Stefan Meuer, Martin Zeier, Thomas Giese
Description
Summary:Calcineurin inhibitors (CNIs) have a narrow therapeutic window; therefore, regular monitoring of the drug is necessary to balance sufficient efficacy with minimal toxicity. Until now, monitoring of immunosuppressive drugs is performed by pharmacokinetic assessments, mainly by trough concentrations (C0) of the drug. All these methods rely on pharmacokinetic data, which does not reflect the biological effects of CNI on the immune system. Several approaches have been undertaken to measure the biologic effects of CNI-based immunosuppression. Recently, a new quantitative analysis of gene expression has been employed to calculate the inhibition of the transcription of NFAT-regulated genes in peripheral blood. Methodological aspects and clinical data on the potential benefit of this specific CNI monitoring assay are discussed.
Item Description:Available online 4 October 2011
Gesehen am 30.07.2018
Physical Description:Online Resource
ISSN:1873-3492
DOI:10.1016/j.cca.2011.09.041